Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

10.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.2K
Amyloid Fibrils03:03

Amyloid Fibrils

5.2K
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network.

Rheumatology (Oxford, England)·2026
Same author

Ophthalmic involvement in VEXAS syndrome and its influence on mortality: insights from the international AIDA network registry.

Frontiers in immunology·2026
Same author

Radiomics to discriminate between axial spondyloarthritis and axial psoriatic arthritis and to predict TNFi therapy persistence.

EULAR rheumatology open·2026
Same author

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.

Seminars in arthritis and rheumatism·2026
Same author

Risk of intestinal involvement in mucocutaneous-onset Behçet's disease: data from the AIDA network registry.

Frontiers in immunology·2026
Same author

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.

Critical reviews in oncology/hematology·2026

Related Experiment Video

Updated: May 1, 2026

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

9.6K

Serum amyloid-A in Behçet's disease.

Antonio Vitale1, Donato Rigante, Giuseppe Lopalco

  • 1Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le Scotte, University of Siena, Siena, Italy. cantariniluca@hotmail.com

Clinical Rheumatology
|March 25, 2014
PubMed
Summary

Serum amyloid-A (SAA) shows potential as a marker for Behçet’s disease (BD) activity. Elevated SAA levels correlate with specific symptoms like oral aphthosis, neurological issues, and ocular disease, and may indicate thrombotic risk in BD patients.

More Related Videos

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

18.0K
SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval
10:48

SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval

Published on: April 23, 2010

22.5K

Related Experiment Videos

Last Updated: May 1, 2026

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

9.6K
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

18.0K
SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval
10:48

SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval

Published on: April 23, 2010

22.5K

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Serum amyloid-A (SAA) is an acute phase protein synthesized by the liver.
  • SAA has been explored as a disease activity marker in various rheumatologic conditions.
  • The role of SAA in Behçet’s disease (BD), a complex inflammatory disorder, remains unclear.

Purpose of the Study:

  • To investigate the potential of Serum amyloid-A (SAA) levels as a marker for disease activity in patients diagnosed with Behçet’s disease (BD).

Main Methods:

  • This study assessed serum levels of SAA in patients with Behçet's disease.
  • Correlation analysis was performed between SAA levels and clinical manifestations of BD.

Main Results:

  • Significantly higher SAA serum levels were observed in patients with oral aphthosis (>30 mg/L), neurological impairment (>50 mg/L), and ocular disease (>150 mg/L).
  • Increased SAA levels may indicate an elevated thrombotic risk in BD patients with existing or concurrent vascular involvement.

Conclusions:

  • Serum amyloid-A (SAA) levels are associated with specific clinical manifestations in Behçet's disease (BD).
  • SAA may serve as a valuable biomarker for monitoring disease activity and identifying thrombotic risk in BD.